A case report of severe hyponatremia secondary to Paxlovid‐induced SIADH

Nirmatrelvir‐ritonavir (Paxlovid) is a brand‐new oral antiviral medication for treating mild to severe COVID‐19. The Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for ritonavir‐nirmatrelvir on December 22, 2021, to treat COVID‐19. We describe a case of mild COVID‐19...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohamed, Sarah, Reda Mostafa, Mostafa, Magdi Eid, Mohamed, AbdelQadir, Yossef Hassan, Abdelghafar, Yomna Ali, Swed, Sarya, Jahshan, Bishara, El‐Radi, Waddah Abd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465720/
https://www.ncbi.nlm.nih.gov/pubmed/37655131
http://dx.doi.org/10.1002/ccr3.7860
_version_ 1785098733742981120
author Mohamed, Sarah
Reda Mostafa, Mostafa
Magdi Eid, Mohamed
AbdelQadir, Yossef Hassan
Abdelghafar, Yomna Ali
Swed, Sarya
Jahshan, Bishara
El‐Radi, Waddah Abd
author_facet Mohamed, Sarah
Reda Mostafa, Mostafa
Magdi Eid, Mohamed
AbdelQadir, Yossef Hassan
Abdelghafar, Yomna Ali
Swed, Sarya
Jahshan, Bishara
El‐Radi, Waddah Abd
author_sort Mohamed, Sarah
collection PubMed
description Nirmatrelvir‐ritonavir (Paxlovid) is a brand‐new oral antiviral medication for treating mild to severe COVID‐19. The Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for ritonavir‐nirmatrelvir on December 22, 2021, to treat COVID‐19. We describe a case of mild COVID‐19 infection who developed severe hyponatremia following the administration of Paxlovid. Clinical and laboratory evaluations suggest SIADH, likely secondary to Paxlovid. The potential side effects of this medication still require further study.
format Online
Article
Text
id pubmed-10465720
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-104657202023-08-31 A case report of severe hyponatremia secondary to Paxlovid‐induced SIADH Mohamed, Sarah Reda Mostafa, Mostafa Magdi Eid, Mohamed AbdelQadir, Yossef Hassan Abdelghafar, Yomna Ali Swed, Sarya Jahshan, Bishara El‐Radi, Waddah Abd Clin Case Rep Case Report Nirmatrelvir‐ritonavir (Paxlovid) is a brand‐new oral antiviral medication for treating mild to severe COVID‐19. The Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for ritonavir‐nirmatrelvir on December 22, 2021, to treat COVID‐19. We describe a case of mild COVID‐19 infection who developed severe hyponatremia following the administration of Paxlovid. Clinical and laboratory evaluations suggest SIADH, likely secondary to Paxlovid. The potential side effects of this medication still require further study. John Wiley and Sons Inc. 2023-08-29 /pmc/articles/PMC10465720/ /pubmed/37655131 http://dx.doi.org/10.1002/ccr3.7860 Text en © 2023 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Case Report
Mohamed, Sarah
Reda Mostafa, Mostafa
Magdi Eid, Mohamed
AbdelQadir, Yossef Hassan
Abdelghafar, Yomna Ali
Swed, Sarya
Jahshan, Bishara
El‐Radi, Waddah Abd
A case report of severe hyponatremia secondary to Paxlovid‐induced SIADH
title A case report of severe hyponatremia secondary to Paxlovid‐induced SIADH
title_full A case report of severe hyponatremia secondary to Paxlovid‐induced SIADH
title_fullStr A case report of severe hyponatremia secondary to Paxlovid‐induced SIADH
title_full_unstemmed A case report of severe hyponatremia secondary to Paxlovid‐induced SIADH
title_short A case report of severe hyponatremia secondary to Paxlovid‐induced SIADH
title_sort case report of severe hyponatremia secondary to paxlovid‐induced siadh
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465720/
https://www.ncbi.nlm.nih.gov/pubmed/37655131
http://dx.doi.org/10.1002/ccr3.7860
work_keys_str_mv AT mohamedsarah acasereportofseverehyponatremiasecondarytopaxlovidinducedsiadh
AT redamostafamostafa acasereportofseverehyponatremiasecondarytopaxlovidinducedsiadh
AT magdieidmohamed acasereportofseverehyponatremiasecondarytopaxlovidinducedsiadh
AT abdelqadiryossefhassan acasereportofseverehyponatremiasecondarytopaxlovidinducedsiadh
AT abdelghafaryomnaali acasereportofseverehyponatremiasecondarytopaxlovidinducedsiadh
AT swedsarya acasereportofseverehyponatremiasecondarytopaxlovidinducedsiadh
AT jahshanbishara acasereportofseverehyponatremiasecondarytopaxlovidinducedsiadh
AT elradiwaddahabd acasereportofseverehyponatremiasecondarytopaxlovidinducedsiadh
AT mohamedsarah casereportofseverehyponatremiasecondarytopaxlovidinducedsiadh
AT redamostafamostafa casereportofseverehyponatremiasecondarytopaxlovidinducedsiadh
AT magdieidmohamed casereportofseverehyponatremiasecondarytopaxlovidinducedsiadh
AT abdelqadiryossefhassan casereportofseverehyponatremiasecondarytopaxlovidinducedsiadh
AT abdelghafaryomnaali casereportofseverehyponatremiasecondarytopaxlovidinducedsiadh
AT swedsarya casereportofseverehyponatremiasecondarytopaxlovidinducedsiadh
AT jahshanbishara casereportofseverehyponatremiasecondarytopaxlovidinducedsiadh
AT elradiwaddahabd casereportofseverehyponatremiasecondarytopaxlovidinducedsiadh

Ejemplares similares